ATE551362T1 - Peptide, die den blutzuckergehalt senken - Google Patents

Peptide, die den blutzuckergehalt senken

Info

Publication number
ATE551362T1
ATE551362T1 AT03005786T AT03005786T ATE551362T1 AT E551362 T1 ATE551362 T1 AT E551362T1 AT 03005786 T AT03005786 T AT 03005786T AT 03005786 T AT03005786 T AT 03005786T AT E551362 T1 ATE551362 T1 AT E551362T1
Authority
AT
Austria
Prior art keywords
peptides
blood sugar
sugar content
lower blood
useful
Prior art date
Application number
AT03005786T
Other languages
English (en)
Inventor
Bjarne Larsen
Jens Mikkelsen
Soren Neve
Original Assignee
Zealand Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zealand Pharma As filed Critical Zealand Pharma As
Application granted granted Critical
Publication of ATE551362T1 publication Critical patent/ATE551362T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
AT03005786T 1999-07-12 2000-07-12 Peptide, die den blutzuckergehalt senken ATE551362T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14359199P 1999-07-12 1999-07-12
EP99610043A EP1076066A1 (de) 1999-07-12 1999-08-09 Peptide zur Senkung des Blutglukosespiegels

Publications (1)

Publication Number Publication Date
ATE551362T1 true ATE551362T1 (de) 2012-04-15

Family

ID=26153727

Family Applications (2)

Application Number Title Priority Date Filing Date
AT03005786T ATE551362T1 (de) 1999-07-12 2000-07-12 Peptide, die den blutzuckergehalt senken
AT00945656T ATE242267T1 (de) 1999-07-12 2000-07-12 Extendin-4 konjugate und ihre medizinische verwendung

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT00945656T ATE242267T1 (de) 1999-07-12 2000-07-12 Extendin-4 konjugate und ihre medizinische verwendung

Country Status (20)

Country Link
US (1) US20070111940A1 (de)
EP (4) EP1076066A1 (de)
JP (4) JP4332314B2 (de)
CN (1) CN1229390C (de)
AT (2) ATE551362T1 (de)
AU (2) AU781338B2 (de)
BE (1) BE2013C033I2 (de)
CA (2) CA2378431C (de)
CY (2) CY1113347T1 (de)
DE (1) DE60003182T2 (de)
DK (3) DK1196444T3 (de)
ES (3) ES2529578T3 (de)
FR (1) FR13C0021I2 (de)
HK (2) HK1058046A1 (de)
IL (4) IL147293A0 (de)
LU (1) LU92175I2 (de)
NZ (1) NZ517012A (de)
PT (3) PT2112161E (de)
SI (2) SI1329458T1 (de)
WO (1) WO2001004156A1 (de)

Families Citing this family (228)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999046283A1 (en) 1998-03-09 1999-09-16 Zealand Pharmaceuticals A/S Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
SE9801571D0 (sv) 1998-05-05 1998-05-05 Wapharm Ab Melanokortin-1-receptorselektiva föreningar
US6444788B1 (en) 1999-03-15 2002-09-03 Novo Nordisk A/S Ion exchange chromatography of GLP-1, analogs and derivatives thereof
US6528486B1 (en) 1999-07-12 2003-03-04 Zealand Pharma A/S Peptide agonists of GLP-1 activity
PT1326630E (pt) 2000-09-18 2008-09-02 Sanos Bioscience As Utilização de péptidos glp-2
US7371721B2 (en) 2000-09-18 2008-05-13 Sanos Bioscience A/S Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes
AU3938402A (en) 2000-12-13 2002-06-24 Lilly Co Eli Chronic treatment regimen using glucagon-like insulinotropic peptides
CN1162446C (zh) 2001-05-10 2004-08-18 上海华谊生物技术有限公司 促胰岛素分泌肽衍生物
CN1158304C (zh) * 2001-05-10 2004-07-21 上海华谊生物技术有限公司 蛙皮抗菌肽衍生物
US20030119734A1 (en) 2001-06-28 2003-06-26 Flink James M. Stable formulation of modified GLP-1
ATE408414T1 (de) 2001-07-31 2008-10-15 Us Gov Health & Human Serv Glp 1 exendin 4 peptidanaloga und deren verwendungen
US8129504B2 (en) 2001-08-30 2012-03-06 Biorexis Technology, Inc. Oral delivery of modified transferrin fusion proteins
US7176278B2 (en) 2001-08-30 2007-02-13 Biorexis Technology, Inc. Modified transferrin fusion proteins
IL160983A0 (en) 2001-09-24 2004-08-31 Imp College Innovations Ltd Use of pyy for preparation of a medicament for modification of feeding behavior
AU2002351752A1 (en) 2001-12-29 2003-07-30 Novo Nordisk A/S Combined use of a glp-1 compound and another drug for treating dyslipidemia
CA2472882A1 (en) 2002-01-10 2003-07-17 Imperial College Innovations Ltd Use of pyy and glp-1, or an agonist thereof, for the modification of feeding behaviour
US7105489B2 (en) * 2002-01-22 2006-09-12 Amylin Pharmaceuticals, Inc. Methods and compositions for treating polycystic ovary syndrome
EP1494704A1 (de) * 2002-04-04 2005-01-12 Novo Nordisk A/S Verwendung von glp-1-rezeptor-agonisten zur behandlung von kardiovascularen krankheiten
AU2003243929B2 (en) * 2002-07-04 2009-06-04 Zp Holding Spv K/S GLP-1 and methods for treating diabetes
JP2006501820A (ja) * 2002-09-06 2006-01-19 バイエル・フアーマシユーチカルズ・コーポレーシヨン 修飾ｇｌｐ−１受容体アゴニストおよびそれらの薬理学的使用法
US7273921B2 (en) 2002-09-25 2007-09-25 Novo Nordisk A/S Method for producing acylated peptides
PL377591A1 (pl) * 2002-10-02 2006-02-06 Zealand Pharma A/S Stabilizowane związki eksendyny-4
EP1559724A4 (de) * 2002-10-11 2006-02-08 Sanwa Kagaku Kenkyusho Co Glp-1 derivate und präparate mit transmukosaler absorption daraus
US6818721B2 (en) 2002-12-02 2004-11-16 Rpo Pty Ltd. Process for producing polysiloxanes and use of the same
EP1688148A1 (de) * 2002-12-03 2006-08-09 Novo Nordisk A/S Behandlung mit Kombinationspräparaten aus Exendin-4 und Thiazolidindionen
AU2003283216A1 (en) * 2002-12-03 2004-06-23 Novo Nordisk A/S Combination treatment using exendin-4 and thiazolidinediones
GB0300571D0 (en) 2003-01-10 2003-02-12 Imp College Innovations Ltd Modification of feeding behaviour
WO2004078777A2 (en) * 2003-03-04 2004-09-16 Biorexis Pharmaceutical Corporation Dipeptidyl-peptidase protected proteins
DE10314610A1 (de) 2003-04-01 2004-11-04 Aventis Pharma Deutschland Gmbh Neues Diphenylazetidinon mit verbesserten physiologischen Eigenschaften, Verfahren zu dessen Herstellung, diese Verbindungen enthaltende Arzneimittel und dessen Verwendung
ES2425221T3 (es) 2003-05-30 2013-10-14 Amylin Pharmaceuticals, Llc Nuevos métodos y composiciones para suministro por vía transmucosa potenciado de péptidos y proteínas
US7008957B2 (en) 2003-07-25 2006-03-07 Sanofi-Aventis Deutschland Gmbh Bicyclic cyanoheterocycles, process for their preparation and their use as medicaments
US7094800B2 (en) 2003-07-25 2006-08-22 Sanofi-Aventis Deutschland Gmbh Cyanopyrrolidides, process for their preparation and their use as medicaments
US7094794B2 (en) 2003-07-28 2006-08-22 Sanofi-Aventis Deutschland Gmbh Substituted thiazole-benzoisothiazole dioxide derivatives, process for their preparation and their use
DE10335092B3 (de) 2003-08-01 2005-02-03 Aventis Pharma Deutschland Gmbh Substituierte Benzoylureido-o-benzoylamide, Verfahren zu deren Herstellung und deren Verwendung
TW200522976A (en) 2003-09-19 2005-07-16 Novo Nordisk As Novel plasma protein affinity tags
CN101380476A (zh) * 2003-09-19 2009-03-11 诺沃挪第克公司 治疗肽的清蛋白结合型衍生物
SI2932981T1 (sl) * 2003-09-19 2021-11-30 Novo Nordisk A/S Albumin-vezavni derivati GLP-1
US20060287221A1 (en) 2003-11-13 2006-12-21 Novo Nordisk A/S Soluble pharmaceutical compositions for parenteral administration comprising a GLP-1 peptide and an insulin peptide of short time action for treatment of diabetes and bulimia
WO2005046716A1 (en) * 2003-11-13 2005-05-26 Novo Nordisk A/S Soluble pharmaceutical compositions for parenteral administration comprising a glp-1 peptide and a insulin peptide of short time action for treatment of diabetes and bulimia
CN104826116A (zh) 2003-11-20 2015-08-12 诺沃挪第克公司 对于生产和用于注射装置中是最佳的含有丙二醇的肽制剂
JP4865565B2 (ja) 2003-12-09 2012-02-01 ノヴォ ノルディスク アー／エス Ｇｌｐ−１アゴニストを用いた食物選択の制御
EP1701731A4 (de) * 2003-12-12 2009-08-05 Einstein Coll Med Glp-1 (9-36) verfahren und zusammensetzungen
WO2005058954A1 (en) 2003-12-18 2005-06-30 Novo Nordisk A/S Novel glp-1 compounds
US8076288B2 (en) 2004-02-11 2011-12-13 Amylin Pharmaceuticals, Inc. Hybrid polypeptides having glucose lowering activity
EP2422807A3 (de) 2004-02-11 2012-05-30 Amylin Pharmaceuticals Inc. Hybridpolypeptide mit auswahlbaren Eigenschaften
CN1318587C (zh) * 2004-04-30 2007-05-30 成都芝田生物工程有限公司 酰胺化Exendin－4多肽的重组制备方法
CN1950078A (zh) 2004-06-11 2007-04-18 诺和诺德公司 使用glp－1激动剂抵抗药物诱发的肥胖
DE102004043153B4 (de) * 2004-09-03 2013-11-21 Philipps-Universität Marburg Erfindung betreffend GLP-1 und Exendin
AU2012202855B2 (en) * 2004-09-03 2015-02-26 Philipps-Universitat Marburg GLP-1 and exendin related invention
JP5107713B2 (ja) 2004-10-07 2012-12-26 ノヴォ ノルディスク アー／エス 遅延性のエキセンディン−４化合物
JP2008515856A (ja) 2004-10-07 2008-05-15 ノボ ノルディスク アクティーゼルスカブ 遅延性ｇｌｐ−１化合物
EP1814581B1 (de) * 2004-11-12 2016-03-16 Novo Nordisk A/S Stabile peptidformulierungen enthaltend ein acyliertes glp-1 analogon und ein basales insulin
DE102004058306A1 (de) * 2004-12-01 2006-07-27 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung von Carboxy-terminal amidierten Peptiden
US8716221B2 (en) 2005-01-14 2014-05-06 Wuxi Grandchamp Pharmaceutical Technology Co., Ltd. Modified exendins and uses thereof
JP4785206B2 (ja) * 2005-01-14 2011-10-05 ウクスィ・グランドチャンプ・ファーマシューティカル・テクノロジー・カンパニー・リミテッド 修飾されたエキセンディン（Ｅｘｅｎｄｉｎｓ）及びその使用
KR20070115947A (ko) 2005-02-11 2007-12-06 아밀린 파마슈티칼스, 인크. 선택가능한 특성들을 가지는 ｇｉｐ 유사체 및 하이브리드폴리펩타이드
US20090286723A1 (en) 2005-02-11 2009-11-19 Amylin Pharmaceuticals, Inc. Hybrid Polypeptides with Selectable Properties
JP2008531730A (ja) 2005-03-04 2008-08-14 キュアーディーエム、インク． Ｉ型真性糖尿病及び他の症状を治療するための方法及び薬学的組成物
EP1863521B1 (de) * 2005-03-18 2014-05-07 Novo Nordisk A/S Erweiterte glp-1-verbindungen
WO2006097535A2 (en) * 2005-03-18 2006-09-21 Novo Nordisk A/S Peptide agonists of the glucagon family with secretin like activity
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
EP2295452A1 (de) 2005-05-04 2011-03-16 Zealand Pharma A/S Glucagon-like peptide-2 (GLP-2) Analoga
EA013821B1 (ru) 2005-05-25 2010-08-30 Кьюрдм, Инк. Проостровковые пептиды человека, их производные и аналоги и способы их применения
BRPI0614649A2 (pt) 2005-08-11 2011-04-12 Amylin Pharmaceuticals Inc polipeptìdeos hìbridos com propriedades selecionáveis
NZ568421A (en) 2005-08-26 2010-01-29 Action Pharma As Therapeutically active alpha-MSH analogues
DE102006031955A1 (de) 2006-07-11 2008-01-17 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung von Insulinanaloga mit dibasischem B-Kettenende
DE102006031962A1 (de) 2006-07-11 2008-01-17 Sanofi-Aventis Deutschland Gmbh Amidiertes Insulin Glargin
ATE524493T1 (de) 2006-07-24 2011-09-15 Biorexis Pharmaceutical Corp Exendin-fusionsproteine
EP2061767B1 (de) 2006-08-08 2014-12-17 Sanofi Arylaminoaryl-alkyl-substituierte Imidazolidin-2,4-dione, Verfahren zu ihrer Herstellung, diese Verbindungen enthaltende Arzneimittel und ihre Verwendung
AU2007293885A1 (en) 2006-09-07 2008-03-13 Takeda Gmbh Combination treatment for diabetes mellitus
KR101527233B1 (ko) 2006-11-08 2015-06-08 질랜드 파마 에이/에스 선택적인 글루카곤 유사 펩티드-2(ｇｌｐ-2) 유사체
JP2010043001A (ja) * 2006-11-09 2010-02-25 Sanwa Kagaku Kenkyusho Co Ltd Ｇｌｐ−１誘導体とその用途
WO2008064306A2 (en) 2006-11-22 2008-05-29 Curedm, Inc. Methods and compositions relating to islet cell neogenesis
TWI428346B (zh) 2006-12-13 2014-03-01 Imp Innovations Ltd 新穎化合物及其等對進食行為影響
RU2413528C2 (ru) 2007-01-18 2011-03-10 Открытое Акционерное Общество "Валента Фармацевтика" Лекарственный препарат для лечения сахарного диабета на основе экзенатида и даларгина, применение и способ лечения
DE102007005045B4 (de) 2007-01-26 2008-12-18 Sanofi-Aventis Phenothiazin Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
WO2008098693A2 (en) * 2007-02-16 2008-08-21 Bayer Healthcare Ag Convergent synthesis of glp-1
WO2008149345A2 (en) 2007-06-04 2008-12-11 Ben-Gurion University Of The Negev Research And Development Authority Tri-aryl compounds and compositions comprising the same
EP2158214B1 (de) 2007-06-15 2011-08-17 Zealand Pharma A/S Glucagonanaloga
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
NZ599756A (en) 2007-08-30 2013-09-27 Curedm Group Holdings Llc Compositions and methods of using proislet peptides and analogs thereof
CN101868476B (zh) 2007-09-05 2015-02-25 诺沃-诺迪斯克有限公司 胰高血糖素样肽-1衍生物及其制药用途
WO2009030774A1 (en) 2007-09-05 2009-03-12 Novo Nordisk A/S Truncated glp-1 derivatives and their therapeutical use
CA2703113A1 (en) 2007-10-27 2009-04-30 F. Hoffmann-La Roche Ag Insulinotropic peptide synthesis using solid and solution phase combination techniques
DE102007054497B3 (de) 2007-11-13 2009-07-23 Sanofi-Aventis Deutschland Gmbh Neue kristalline Diphenylazetidinonhydrate und Verfahren zu deren Herstellung
BRPI0820535B8 (pt) 2007-11-16 2021-05-25 Novo Nordisk As composições farmacêuticas contendo insulina e um peptídeo insulinotrópico
DE102008003568A1 (de) 2008-01-09 2009-07-16 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
DE102008025008A1 (de) 2008-05-24 2009-11-26 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
CN101970476B (zh) 2008-01-09 2014-08-27 塞诺菲-安万特德国有限公司 具有超延迟时效特征的胰岛素衍生物
DE102008003566A1 (de) 2008-01-09 2009-07-16 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
EP2229407B1 (de) 2008-01-09 2016-11-16 Sanofi-Aventis Deutschland GmbH Neue insulinderivate mit extrem verzögertem zeit- / wirkungsprofil
DE102008025007A1 (de) 2008-05-24 2009-11-26 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
CA2729296A1 (en) * 2008-06-17 2010-01-28 Richard D. Dimarchi Gip-based mixed agonists for treatment of metabolic disorders and obesity
EP2926825A1 (de) 2008-06-27 2015-10-07 Duke University Therapeutika mit elastinähnlichen peptiden
US8470841B2 (en) 2008-07-09 2013-06-25 Sanofi Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
US8865868B2 (en) 2008-08-06 2014-10-21 Novo Nordisk Healthcare Ag Conjugated proteins with prolonged in vivo efficacy
DE102009038210A1 (de) 2009-08-20 2011-03-03 Sanofi-Aventis Deutschland Gmbh Kombination von einem Insulin und einem GLP-1-Agonisten
DE102008051834A1 (de) 2008-10-17 2010-04-22 Sanofi-Aventis Deutschland Gmbh Kombination von einem Insulin und einem GLP-1-Agonisten
RS59913B1 (sr) 2008-10-17 2020-03-31 Sanofi Aventis Deutschland Kombinacija insulina i glp-1-agonista
DE102008053048A1 (de) 2008-10-24 2010-04-29 Sanofi-Aventis Deutschland Gmbh Kombination von einem Insulin und einem GLP-1-Agonisten
US8889618B2 (en) 2008-11-07 2014-11-18 The General Hospital Corporation C-terminal fragments of glucagon-like peptide-1 (GLP-1)
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
PT2373681T (pt) 2008-12-10 2017-04-11 Glaxosmithkline Llc Composições farmacêuticas de albiglutida
AU2008365556A1 (en) 2008-12-15 2011-07-21 Zealand Pharma A/S Glucagon analogues
ES2439499T3 (es) 2008-12-15 2014-01-23 Zealand Pharma A/S Análogos de glucagón
MX2011006315A (es) 2008-12-15 2011-09-22 Zealand Pharma As Analogos de glucagon.
CA2747109A1 (en) 2008-12-15 2010-06-24 Zealand Pharma A/S Glucagon analogues
AU2010207725B2 (en) 2009-01-22 2015-06-11 Novo Nordisk Health Care Ag Stable growth hormone compounds
WO2011003823A1 (de) * 2009-07-06 2011-01-13 Sanofi-Aventis Deutschland Gmbh Langsamwirkende insulinzubereitungen
MY159865A (en) * 2009-07-06 2017-02-15 Sanofi Aventis Deutschland Aqueous insulin preparations containing methionine
EA022816B1 (ru) 2009-07-13 2016-03-31 Зилэнд Фарма А/С Ацилированные аналоги глюкагона
CN101987868B (zh) * 2009-07-30 2013-09-04 江苏豪森医药集团有限公司 Glp-1类似物的衍生物或其可药用盐和用途
JP6086528B2 (ja) 2009-08-06 2017-03-01 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー 長期のインビボ有効性を有する成長ホルモン
RU2012111354A (ru) 2009-08-26 2013-10-10 Санофи Новые кристаллические гидраты фторгликозидов, содержащие их фармацевтические препараты и их использование
EP2491054A2 (de) 2009-10-22 2012-08-29 Cadila Healthcare Limited Auf kurzkettigen peptidomimetika basierende oral aktive glp-1-agonisten und glucagonrezeptor-antagonisten
AU2009238272B2 (en) * 2009-11-13 2014-05-08 Sanofi-Aventis Deutschland Gmbh Method of treatment of diabetes type 2 comprising add-on therapy to metformin
SI2324853T1 (sl) 2009-11-13 2015-12-31 Sanofi-Aventis Deutschland Gmbh Liksisenatid kot dodatek metforminu pri zdravljenju sladkorne bolezni tipa 2
ES2398012T5 (es) 2009-11-13 2020-02-26 Sanofi Aventis Deutschland Lixisenatide como terapia complementaria a insulina glargina y metformina para tratar diabetes de tipo 2
DE102010011919A1 (de) 2010-03-18 2011-09-22 Sanofi-Aventis Deutschland Gmbh Pharmazeutische Zusammensetzung umfassend einen GLP-1-Agonisten und Methionin
JP2011105609A (ja) * 2009-11-13 2011-06-02 Sanofi-Aventis Deutschland Gmbh メトホルミンへの付加療法を含む２型糖尿病の治療方法
ES2534191T3 (es) 2009-11-13 2015-04-20 Sanofi-Aventis Deutschland Gmbh Composición farmacéutica que comprende un agonista de GLP-1, una insulina y metionina
KR101337322B1 (ko) 2009-11-13 2013-12-06 사노피-아벤티스 도이칠란트 게엠베하 Ｇｌｐ-1 효능제 및 메티오닌을 포함하는 약제학적 조성물
EP2525809B1 (de) 2010-01-20 2016-08-03 Zealand Pharma A/S Glukagon-glp1 doppelagonisten zur behandlung von herzkrankheiten
BR112012018162A2 (pt) 2010-01-22 2017-10-03 Novo Nordisk Healthcare Ag Compostos de hormônio do crescimento estáveis
BR112012018116B1 (pt) 2010-01-22 2022-06-21 Novo Nordisk Health Care Ag Conjugados de hormônio do crescimento com eficácia in vivo prolongada
US9422330B2 (en) 2010-03-01 2016-08-23 Novo Nordisk A/S Preparative RP-HPLC method for purifying peptides
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2555791B1 (de) 2010-04-09 2017-11-01 Sinai Health System Verfahren zur behandlung von erkrankungen des magen-darm-trakts mittels eines glp-1-agonisten
DE102010015123A1 (de) 2010-04-16 2011-10-20 Sanofi-Aventis Deutschland Gmbh Benzylamidische Diphenylazetidinone, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
KR20130098873A (ko) 2010-04-27 2013-09-05 질랜드 파마 에이/에스 Glp-1 수용체 작용제 및 가스트린의 펩타이드 접합체 및 그의 용도
US8691763B2 (en) 2010-05-04 2014-04-08 Glaxosmithkline Llc Methods for treating or preventing cardiovascular disorders and providing cardiovascular protection
AU2011202239C1 (en) 2010-05-19 2017-03-16 Sanofi Long-acting formulations of insulins
EP2389945A1 (de) 2010-05-28 2011-11-30 Sanofi-Aventis Deutschland GmbH Pharmazeutische Zusammensetzung mit AVE0010 und Insulin glargin
CN101891823B (zh) * 2010-06-11 2012-10-03 北京东方百泰生物科技有限公司 一种Exendin-4及其类似物融合蛋白
WO2011157827A1 (de) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
AR081975A1 (es) 2010-06-23 2012-10-31 Zealand Pharma As Analogos de glucagon
SG186764A1 (en) 2010-06-24 2013-02-28 Zealand Pharma As Glucagon analogues
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
BR112013004756B1 (pt) 2010-08-30 2020-04-28 Sanofi Aventis Deutschland uso de ave0010 para a fabricação de um medicamento para o tratamento da diabetes melito tipo 2
WO2012061466A2 (en) 2010-11-02 2012-05-10 The General Hospital Corporation Methods for treating steatotic disease
PL2651398T3 (pl) 2010-12-16 2018-05-30 Novo Nordisk A/S Stałe kompozycje zawierające agonistę GLP-1 i sól kwasu N-(8-(2-hydroksybenzoilo)amino)kaprylowego
WO2012104342A1 (en) 2011-02-02 2012-08-09 Sanofi-Aventis Deutschland Gmbh Prevention of hypoglycaemia in diabetes mellitus type 2 patients
EP2683698B1 (de) 2011-03-08 2017-10-04 Sanofi Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120052A1 (de) 2011-03-08 2012-09-13 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8846666B2 (en) 2011-03-08 2014-09-30 Sanofi Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
EP2683705B1 (de) 2011-03-08 2015-04-22 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683703B1 (de) 2011-03-08 2015-05-27 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120053A1 (de) 2011-03-08 2012-09-13 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683700B1 (de) 2011-03-08 2015-02-18 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683702B1 (de) 2011-03-08 2014-12-24 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US20120277147A1 (en) 2011-03-29 2012-11-01 Sanofi-Aventis Deutschland Gmbh Prevention of hypoglycaemia in diabetes mellitus type 2 patients
EP3225631B1 (de) 2011-04-12 2019-01-09 Novo Nordisk A/S Zweifach acylierte glp-1-derivate
US20130040878A1 (en) 2011-05-13 2013-02-14 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for use in the treatment of diabetes type 2 patients
US8735349B2 (en) 2011-05-13 2014-05-27 Sanofi-Aventis Deutschland Gmbh Method for improving glucose tolerance in a diabetes type 2 patient of younger than 50 years and having postprandial plasma glucose concentration of at least 14 mmol/L
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
JP6442284B2 (ja) 2011-05-13 2018-12-19 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング ２型糖尿病の処置のためのリキシセナチド及びメトホルミン
EP2729157B1 (de) 2011-07-06 2019-01-16 The General Hospital Corporation Ein pentapeptid aus dem c-terminus des glucagon-like peptids-1 (glp-1) zur verwendung in der behandlung
PL2750699T3 (pl) 2011-08-29 2015-12-31 Sanofi Aventis Deutschland Kombinacja farmaceutyczna do stosowania w kontroli glikemii u pacjentów z cukrzycą typu 2
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2567959B1 (de) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridin-4-carbonsäureamid-derivate als kinaseinhibitoren
EP2760862B1 (de) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridin-4-carbonsäureamidderivate als kinaseinhibitoren
EP2763691A1 (de) 2011-10-04 2014-08-13 Sanofi-Aventis Deutschland GmbH Glp-1-agonist zur verwendung bei der behandlung von stenose und/oder verstopfungen im pankreasgangsystem
EP2763690B1 (de) 2011-10-04 2015-11-25 Sanofi-Aventis Deutschland GmbH Lixisenatide zur behandlung von stenosen oder/und obstruktionen im pankreasgangsystem
CN107693783A (zh) 2011-10-28 2018-02-16 赛诺菲-安万特德国有限公司 2型糖尿病的治疗方案
AR088636A1 (es) 2011-11-03 2014-06-25 Zealand Pharma As Conjugados peptidicos de un agonista del receptor de glp-1 y gastrina
CN103087174B (zh) * 2011-11-03 2015-11-18 华东师范大学 一种glp-1衍生物dlg3312及其固相化学合成方法
JP2015500823A (ja) 2011-12-09 2015-01-08 ノヴォ ノルディスク アー／エス Ｇｌｐ−１アゴニスト
EP2793931A2 (de) 2011-12-23 2014-10-29 Zealand Pharma A/S Glucagon-analoga
ES2952874T3 (es) 2012-03-22 2023-11-06 Novo Nordisk As Composiciones de péptidos GLP-1 y preparación de estas
HUE042757T2 (hu) 2012-03-22 2019-07-29 Novo Nordisk As Szállító szert tartalmazó készítmények és elõállításuk
EP2844670B1 (de) 2012-05-03 2017-12-06 Zealand Pharma A/S Glucagon-artige peptid-2-analoga (glp-2-)analoga
SG11201407137PA (en) 2012-05-03 2014-11-27 Zealand Pharma As Gip-glp-1 dual agonist compounds and methods
JP6517690B2 (ja) 2012-06-20 2019-05-22 ノヴォ ノルディスク アー／エス ペプチド及び送達剤を含む錠剤製剤
CN104662038B (zh) 2012-07-23 2018-11-06 西兰制药公司 胰高血糖素类似物
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
CN105142621A (zh) 2012-10-24 2015-12-09 国家健康科学研究所 用于预防或治疗糖尿病和促进β-细胞存活的TPL2激酶抑制剂
WO2014077575A1 (ko) * 2012-11-13 2014-05-22 다인바이오 주식회사 덱에이 효소반응으로 조제한 항비만 및 항당뇨 효능을 갖는 한천 유래 네오아가로올리고당 복합 조성물
KR20140088837A (ko) * 2013-01-03 2014-07-11 한미약품 주식회사 Ｎ-말단 전하가 변형된 인슐린 분비 펩티드 유도체
TWI641381B (zh) 2013-02-04 2018-11-21 法商賽諾菲公司 胰島素類似物及／或胰島素衍生物之穩定化醫藥調配物
EP3517122A1 (de) 2013-04-03 2019-07-31 Sanofi Behandlung von diabetes mellitus durch langzeitwirkende formulierungen von insulinen
US11045523B2 (en) 2013-04-05 2021-06-29 Novo Nordisk Healthcare Ag Formulation of growth hormone albumin-binder conjugate
AR096789A1 (es) 2013-07-04 2016-02-03 Novo Nordisk As Derivados de péptidos similares a glp-1 y usos de los mismos
GB201315335D0 (en) * 2013-08-29 2013-10-09 Of Singapore Amino diacids containing peptide modifiers
US9988429B2 (en) * 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
MY176022A (en) 2013-10-17 2020-07-21 Boehringer Ingelheim Int Acylated glucagon analogues
US10111880B2 (en) 2013-11-05 2018-10-30 Ben-Gurion University Of The Negev Research And Development Authority Compounds for the treatment of diabetes and disease complications arising from same
KR102310389B1 (ko) 2013-11-06 2021-10-13 질랜드 파마 에이/에스 Ｇｉｐ-ｇｌｐ-1 이원 효능제 화합물 및 방법
TR201902516T4 (tr) 2013-11-06 2019-03-21 Zealand Pharma As Glukagon-glp-1-gıp üçlü agonist bileşikleri.
CN103613657B (zh) * 2013-11-28 2016-01-13 孙玉琨 缩短肽链的Exendin4及其基因工程应用
KR20160104726A (ko) 2014-01-09 2016-09-05 사노피 인슐린 유사체 및/또는 인슐린 유도체의 안정화된 무글리세롤 약제학적 제형
SG11201604710XA (en) 2014-01-09 2016-07-28 Sanofi Sa Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
KR20160101195A (ko) 2014-01-09 2016-08-24 사노피 인슐린 아스파트의 안정화된 약제학적 제형
KR101768446B1 (ko) * 2014-03-21 2017-08-17 애니젠 주식회사 신규한 엑세나타이드 유사체 및 그의 용도
DK3212218T3 (da) 2014-10-29 2021-08-30 Zealand Pharma As GIP-agonistforbindelser og fremgangsmåder
HRP20230470T1 (hr) 2014-12-12 2023-07-21 Sanofi-Aventis Deutschland Gmbh Formulacija fiksnog omjera inzulin glargin/liksisenatid
US20160235818A1 (en) 2015-01-16 2016-08-18 Sanofi-Aventis Deutschland Gmbh Treatment of Pediatric Type 2 Diabetes Mellitus Patients
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
EP3273981B1 (de) 2015-03-24 2020-04-29 INSERM - Institut National de la Santé et de la Recherche Médicale Verfahren und pharmazeutische zusammensetzung zur verwendung bei der behandlung von diabetes
CN107636010B (zh) 2015-04-16 2021-10-01 西兰制药公司 酰化胰高血糖素类似物
CA3043151A1 (en) 2016-12-09 2018-06-14 Zealand Pharma A/S Acylated glp-1/glp-2 dual agonists
IL271245B2 (en) 2017-06-16 2023-10-01 Zealand Pharma As Dosing regimen for administration of glucagon-like peptide analog (GLP-2) 2
FR3082426A1 (fr) 2018-06-14 2019-12-20 Adocia Compositions sous forme d'une solution aqueuse injectable comprenant au moins de l'insuline humaine a21g et un suppresseur de glucagon a action prandiale
ES2917893T3 (es) 2017-07-27 2022-07-12 Adocia Composiciones en forma de una solución acuosa inyectable que comprenden al menos insulina humana A21G y un supresor de glucagón con acción prandial
CN111050750A (zh) 2017-08-24 2020-04-21 诺沃挪第克公司 Glp-1组合物及其用途
MX2020007598A (es) 2018-02-02 2020-09-03 Novo Nordisk As Composiciones solidas que comprenden un agonista del peptido similar al glucagon tipo 1 (glp-1), una sal del acido n-(8-(2-hidroxibenzoil)amino)caprilico y un lubricante.
US11560402B2 (en) 2018-04-10 2023-01-24 Sanofi-Aventis Deutschland Gmbh Method for cleavage of solid phase-bound peptides from the solid phase
EP3774838B1 (de) 2018-04-10 2022-08-10 Sanofi-Aventis Deutschland GmbH Lixisenatidsynthese mit verkappung
FR3083700B1 (fr) 2018-07-13 2021-03-12 Adocia Formulation thermostable d'insuline humaine a21g
EP3628682A1 (de) 2018-09-28 2020-04-01 Zealand Pharma A/S Formulierungen von analoga des glucagon-like-peptid-2 (glp-2)
EP3628683A1 (de) 2018-09-28 2020-04-01 Zealand Pharma A/S Formulierungen von analoga des glucagon-like-peptid-2 (glp-2)
TWI799680B (zh) * 2019-01-29 2023-04-21 美商美國禮來大藥廠 製備gip/glp1雙重促效劑之方法
CN109721653B (zh) * 2019-03-05 2023-02-03 嘉兴学院 一种胰高血糖素样肽-1片段类似物及其应用
US20210093698A1 (en) 2019-09-13 2021-04-01 Sanofi Treatment of type 2 diabetes mellitus
EP3858373A1 (de) 2020-01-31 2021-08-04 Adocia Zusammensetzungen mit mindestens einem amylin-rezeptor-agonisten und einem glp-1-rezeptor-agonisten
KR20220143036A (ko) 2020-02-18 2022-10-24 노보 노르디스크 에이/에스 약학적 제형
EP3915572A1 (de) 2020-05-29 2021-12-01 Adocia Pharmazeutische zusammensetzung in form einer injizierbaren wässrigen lösung mit mindestens einem schnell wirkenden insulinanalogon und einem glucagon-suppressor mit prandialer wirkung
EP3915571A1 (de) 2020-05-29 2021-12-01 Adocia Pharmazeutische zusammensetzung in form einer injizierbaren wässrigen lösung mit mindestens einem schnell wirkenden insulinanalogon und einem glucagon-suppressor mit prandialer wirkung
AU2021397877A1 (en) * 2020-12-11 2023-07-06 Ip2Ipo Innovations Limited Novel compounds
EP4129324A1 (de) 2021-08-02 2023-02-08 Adocia Zusammensetzungen mit mindestens einem amylin-rezeptor-agonisten und einem glp-1-rezeptor-agonisten
KR20240055083A (ko) 2021-09-10 2024-04-26 질랜드 파마 에이/에스 글루카곤 유사 펩티드-2(glp-2) 아날로그를 포함하는 조성물을 제제화하는 방법
WO2023118416A1 (en) 2021-12-23 2023-06-29 Zealand Pharma A/S Processes for synthesizing glucagon-like-peptide 2 (glp-2) analogues
WO2024068848A1 (en) 2022-09-28 2024-04-04 Zealand Pharma A/S Methods for treating obesity

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4288627A (en) 1980-02-12 1981-09-08 Phillips Petroleum Company Oxidation of thiols employing cobalt molybdate/triethylamine catalyst
US5545618A (en) 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
AU639570B2 (en) 1990-05-09 1993-07-29 Novozymes A/S A cellulase preparation comprising an endoglucanase enzyme
DK36392D0 (da) 1992-03-19 1992-03-19 Novo Nordisk As Anvendelse af kemisk forbindelse
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
ATE417622T1 (de) * 1996-08-08 2009-01-15 Amylin Pharmaceuticals Inc Regulation gastrointestinaler beweglichkeit
US6006753A (en) 1996-08-30 1999-12-28 Eli Lilly And Company Use of GLP-1 or analogs to abolish catabolic changes after surgery
US6277819B1 (en) 1996-08-30 2001-08-21 Eli Lilly And Company Use of GLP-1 or analogs in treatment of myocardial infarction
ATE356830T1 (de) * 1996-08-30 2007-04-15 Novo Nordisk As Glp-1 derivate
AU724326B2 (en) * 1996-09-09 2000-09-14 Zealand Pharmaceuticals A/S Peptide prodrugs containing an alpha-hydroxyacid linker
UA65549C2 (uk) 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
WO1998022577A1 (en) * 1996-11-15 1998-05-28 Maria Grazia Masucci Fusion proteins having increased half-lives
WO1998030231A1 (en) * 1997-01-07 1998-07-16 Amylin Pharmaceuticals, Inc. Use of exendins and agonists thereof for the reduction of food intake
EP0981611A1 (de) 1997-02-05 2000-03-01 1149336 Ontario Inc. Für ProeXENDIN KODIERENDE POLYNUKLEOTIDE, Verfahren UND ANWENDUNGEN derselben
US5846937A (en) 1997-03-03 1998-12-08 1149336 Ontario Inc. Method of using exendin and GLP-1 to affect the central nervous system
EP1019077B2 (de) * 1997-08-08 2010-12-22 Amylin Pharmaceuticals, Inc. Neue exendinagonist verbindungen
EP1066314B1 (de) * 1997-11-14 2007-12-26 Amylin Pharmaceuticals, Inc. Neuartige exendin agonisten
BR9814189A (pt) * 1997-11-14 2000-10-03 Amylin Pharmaceuticals Inc "compostos agonistas da exendina"
AU759058C (en) 1998-02-13 2005-09-15 Amylin Pharmaceuticals, Inc. Inotropic and diuretic effects of exendin and GLP-1
EP1062240B1 (de) 1998-02-27 2010-04-28 Novo Nordisk A/S N-terminal veränderte glp-1 abkömmlinge
WO1999043708A1 (en) * 1998-02-27 1999-09-02 Novo Nordisk A/S Glp-1 derivatives of glp-1 and exendin with protracted profile of action
WO1999046283A1 (en) * 1998-03-09 1999-09-16 Zealand Pharmaceuticals A/S Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
US6451974B1 (en) * 1999-03-17 2002-09-17 Novo Nordisk A/S Method of acylating peptides and novel acylating agents
BR0010705A (pt) * 1999-04-30 2002-02-05 Amylin Pharmaceuticals Inc Exendinas modificadas e agonistas da exendina
US6528486B1 (en) * 1999-07-12 2003-03-04 Zealand Pharma A/S Peptide agonists of GLP-1 activity
AU2003243929B2 (en) * 2002-07-04 2009-06-04 Zp Holding Spv K/S GLP-1 and methods for treating diabetes
PL377591A1 (pl) * 2002-10-02 2006-02-06 Zealand Pharma A/S Stabilizowane związki eksendyny-4

Also Published As

Publication number Publication date
HK1058046A1 (en) 2004-04-30
JP5553742B2 (ja) 2014-07-16
PT1196444E (pt) 2003-10-31
EP2112161A2 (de) 2009-10-28
ES2200892T3 (es) 2004-03-16
JP2007001987A (ja) 2007-01-11
JP5414144B2 (ja) 2014-02-12
EP2112161B1 (de) 2014-11-05
HK1135119A1 (en) 2010-05-28
IL147293A (en) 2007-12-03
NZ517012A (en) 2003-02-28
ES2529578T3 (es) 2015-02-23
AU2005203735A1 (en) 2005-09-29
DK1329458T3 (da) 2012-07-16
FR13C0021I2 (fr) 2013-08-16
DK1196444T3 (da) 2003-09-29
DE60003182T2 (de) 2004-05-06
CA2378431C (en) 2010-02-09
ES2384963T9 (es) 2012-10-16
JP2011102305A (ja) 2011-05-26
JP2014169296A (ja) 2014-09-18
ATE242267T1 (de) 2003-06-15
JP4332314B2 (ja) 2009-09-16
ES2384963T3 (es) 2012-07-16
CA2378431A1 (en) 2001-01-18
EP1196444A1 (de) 2002-04-17
CY2013032I2 (el) 2015-11-04
EP2112161A3 (de) 2010-04-28
CN1376166A (zh) 2002-10-23
EP1196444B1 (de) 2003-06-04
DK1329458T5 (da) 2013-02-11
PT2112161E (pt) 2015-02-10
CA2680437A1 (en) 2001-01-18
AU5966000A (en) 2001-01-30
DK2112161T3 (en) 2015-01-19
CY2013032I1 (el) 2015-11-04
AU781338B2 (en) 2005-05-19
CY1113347T1 (el) 2016-06-22
IL206445A (en) 2011-09-27
IL185763A (en) 2012-04-30
IL206445A0 (en) 2011-07-31
EP1329458B1 (de) 2012-03-28
SI2112161T1 (sl) 2015-02-27
EP1329458A2 (de) 2003-07-23
FR13C0021I1 (de) 2013-05-03
SI1329458T1 (sl) 2012-07-31
IL147293A0 (en) 2002-08-14
CN1229390C (zh) 2005-11-30
PT1329458E (pt) 2012-07-03
LU92175I2 (fr) 2013-05-27
EP1329458B9 (de) 2012-09-12
EP1196444B8 (de) 2003-08-06
JP2003505347A (ja) 2003-02-12
BE2013C033I2 (de) 2019-10-16
EP1076066A1 (de) 2001-02-14
US20070111940A1 (en) 2007-05-17
AU2005203735B2 (en) 2009-03-19
DE60003182D1 (de) 2003-07-10
WO2001004156A1 (en) 2001-01-18
EP1329458A3 (de) 2003-12-17
IL185763A0 (en) 2008-01-06

Similar Documents

Publication Publication Date Title
ATE551362T1 (de) Peptide, die den blutzuckergehalt senken
ATE444967T1 (de) Spezifische bindungsmittel von human angiopoietin-2
EA200100939A1 (ru) Продолжительно действующие инсулинотропные пептиды
MY137181A (en) Pulmonary administration of chemically modified insulin
HUP0400466A2 (hu) G-CSF konjugátumok
EP1790728A3 (de) Bildgebende Verfahren, Diagnose und Behandlung von Krankheiten
HUP0500637A2 (hu) Neublasztin polimer konjugátumai és alkalmazási eljárásai
EA200000909A1 (ru) ФОРМА VI 5,6-ДИХЛОР-2-(ИЗОПРОПИЛАМИНО)-1-(b-L-РИБОФУРАНОЗИЛ)-1H-БЕНЗИМИДАЗОЛА
CY1115962T1 (el) Πεπτιδια που μειωνουν τα επιπεδα της γλυκοζης στο αιμα
ATE224730T1 (de) Mittel zur behandlung von pigmentierungsstörungen
TW200635953A (en) Specific binding agents of human angiopoietin-2
HUP9801869A2 (hu) Készítmény az L-karnitinszint megnövelésére emberben